Yüklüyor......
First-in-human Phase II trial of the Botanical Formulation PHY906 with Capecitabine as Second-line Therapy in Patients with Advanced Pancreatic Cancer
BACKGROUND: Preclinical studies showed a Chinese botanical formula, PHY906, has synergistic anti-tumor activity with capecitabine. Our phase I study determined maximal tolerated dose of capecitabine 1500mg/m(2) BID day 1–7 and PHY906 800mg BID day 1–4 every two weeks. We conducted this phase II stud...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2013
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4123311/ https://ncbi.nlm.nih.gov/pubmed/24297682 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-013-2359-7 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|